New Zealand markets closed

Genfit S.A. (GNFTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.98000.0000 (0.00%)
At close: 12:31PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9800
Open2.9800
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.9800 - 2.9800
52-week range2.9800 - 4.3900
Volume800
Avg. volume32
Market cap178.771M
Beta (5Y monthly)0.86
PE ratio (TTM)N/A
EPS (TTM)-0.4100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.70
  • GlobeNewswire

    GENFIT Announces Revenues and Cash Position as of December 31, 2023

    Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Upcoming FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liv

  • GlobeNewswire

    GENFIT Announces 2024 Financial Calendar

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024. 2024 Financial Calendar February 29, 2024 Publication of revenue and cash position at December 31, 2023 April 4, 2024 Publication of Full Year 2023 financial statements The

  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity accoun